Plasma concentration, cardiorespiratory and analgesic effects of ketamine-fentanyl infusion in dogs submitted to mastectomy

Rauane Sousa de Moura¹, Isabela Plaza Bittar¹, Janaine Hilbig Gomes¹, Yan Victor Rodrigues de Oliveira¹, Gladsthon Divino de Sousa Filho¹, Glauco Cézar Fragola de Faria Soares², Eliana Martins Lima² and Leandro Guimarães Franco¹*

Abstract

Background: The analgesic and cardiorespiratory effects of ketamine, fentanyl, or ketamine-fentanyl constant rate infusion (CRI) in dogs undergoing mastectomy were evaluated. Seventeen female dogs received CRI of ketamine (GK [n = 6]: bolus 0.5 mg/kg; CRI 20 µg/kg/min in intra- and postoperative periods), fentanyl (GF [n = 5]: bolus 20 µg/kg; intraoperative CRI 5 20 µg/kg/hour and postoperative CRI 2 20 µg/kg/hour), or combination of ketamine-fentanyl (GKF [n = 6]: aforementioned doses) for 8 h. Cardiorespiratory, blood gas analyses, plasma drug concentrations, sedation score (SS), Pain Scores were evaluated.

Results: The heart rate decreased in the GF and GKF (p < 0.04); the mean arterial pressure was lower in the GKF than in the GK at 35 min (p < 0.001). Maximum plasma concentrations were observed 5 min after bolus in the GK (2847.06 ± 2903.03 ng/mL) and GKF (2811.20 ± 1931.76 ng/mL). Plasma concentration in intraoperative period of ketamine was of > 100 ng/mL in 5/5 and 2/5 animals in the GKF and GK, respectively; and > 1.1 ng/mL of fentanyl in 4/5 and 3/5 in GKF and GF, respectively.

Conclusion: Ketamine with/without fentanyl provided analgesia without significant cardiorespiratory and guaranteed the minimal plasma levels with analgesic potential during the 8 h.

Keywords: Analgesia, Constant rate infusion, Mechanical nociceptive threshold, Pharmacokinetics

Introduction

The management of perioperative pain is a challenge in veterinary medicine, which may be associated with inadequate control in the postoperative period, culminating in the development of chronic pain and reduction of quality of life [1, 2], especially in more complex procedures, such as mastectomies, facts that have been well described in human patients [3].

The use of opioids to control pain in dogs undergoing mastectomy is relatively high and has yielded satisfactory results short term after the surgery. Within the class, advantages of fentanyl use include rapid onset [4], rapid recovery, and potent analgesic effect. Limitations of fentanyl use include opioid-induced significant respiratory depression [5, 6] and low residual analgesic effect [7], which lead to an increase in postoperative analgesic requirement [8]. The use of subanaesthetic doses of ketamine, reportedly has important analgesic properties that contribute to the modulation of central sensitization [8], contributing to the prevention of hyperalgesia [9].
In dogs, subanaesthetic doses of ketamine in CRI was considered safe [10], with better postoperative analgesia, reduced need for additional opioid administration [9], and reduced requirement for general anaesthetics [11]. The use of ketamine as a single analgesic remains controversial. In dogs undergoing mastectomy the use of the drug in low doses, and not associated with opioids, has not been able to promote effective analgesia [12], its use being recommended in association with other drugs in multimodal therapy [9]. In multimodal therapy, ketamine has been shown to decrease the requirement for analgesics in the postoperative period, and to promote long-term analgesia [13]. However, evaluation periods of such studies were limited to the immediate postoperative periods of up to 2 h. Effects of using prolonged infusions for controlling postoperative pain in late postoperative period have not yet been verified.

This study aimed to evaluate perioperative analgesic and cardiorespiratory effects of ketamine, fentanyl, or ketamine-fentanyl constant rate infusion in dogs undergoing unilateral mastectomy. We hypothesized that ketamine-fentanyl combination would promote analgesia, decreasing the need of rescue analgesic protocols, to a greater degree than would ketamine or fentanyl alone in dogs.

Materials and methods

Animals

Seventeen adult female client-owned dogs of different breeds weighing 11.82 ± 7.74 kg that were diagnosed with breast cancer after examination of cytology, with cancer stages I and II [14], and had surgical indication for unilateral total mastectomy were included. Animals with comorbidities, such as neoplasms from non-mammary tissue, metastasis presented in thoracic X-rays or abdominal ultrasound, abnormal laboratory test results (full blood count, creatinine, alanine aminotransferase, total protein and fractions), life-threatening arrhythmias, obesity, considered ASA Physical Status Classification ≥ III or with altered behavior, such as aggressive temperament were excluded from the study.

Procedure

The animals were admitted 24 h before the surgical procedure and were subjected to a 12 h food fast and a 2 h water fast. Morphine (0.5 mg/kg; intramuscularly [IM]; DiMorf; Cristália Prod. Quim. Farm. Ltda, Brazil) was administered as premedication. Fifteen minutes later, a 20 G catheter was placed in the right cephalic vein for inducing anesthesia with propofol (5.0 mg/kg; intravenously [IV]; Provine; União Química, Brazil). The dogs were intubated using a cuffed endotracheal tube which met the size of the animal, and the endotracheal tube was connected to a rebreathing system maintained with isoflurane (Isoflurane; BioChimico, Brazil) in 80% oxygen. The isoflurane vaporizer dial was adjusted to deliver a sufficient concentration for maintenance of surgical plan, based on clinical signs, including absence of palpebral reflex, absence of jaw tone, and maintenance of invasive mean arterial pressure (MAP) between 60 and 90 mmHg [11]. Animals were maintained on synchronized intermittent mandatory ventilation (SIMV) (Fabius Plus; Drägerwerk AG & Co., Germany), with the ventilator set to a minimum respiratory rate (fR) of 10 breaths/min. Subsequently, a 22 G catheter was introduced into the right dorsal pedal artery for monitoring blood pressure [systolic arterial pressure (SAP), diastolic arterial pressure (DAP), and MAP] and sampling arterial blood for blood gas and pharmacokinetic analyses.

Anaesthetic monitoring was performed using a multiparameter monitor (Datex Ohmeda; GE Healthcare, USA) and included invasive blood pressure assessment (systolic, diastolic and mean), cardiac rhythm using an electrocardiogram (lead DII, 25 mm second^{-1}), oxygen saturation using a pulse oximeter (positioned on the animals’ tongue), and end-tidal partial pressure of carbon dioxide in the expired gas using a mainstream capnograph (positioned at the distal end of the endotracheal tube).

The mastectomy was performed by an experienced surgeon as described by Fossum and colleagues [15]. After the end of the surgery, the animals were hospitalized for 24. At the end of the infusion the bitches received meloxicam (0.1 mg/kg; Maxicam 0.2%; Ourofino Saúde Animal, Brazil) intravenously (IV), and after hospital discharge, dogs were prescribed meloxicam (0.1 mg/kg) for oral administration every 24 h and metamizol (25 mg/kg PO SOS).

Study design

Animals were randomly assigned to three experimental groups, using with a software (Microsoft Excel 2007), depending on the IV treatment protocol: (1) ketamine (Ketamine Agener; União Química, Brazil) [group ketamine (GK) (n=6)]: bolus 0.5 mg/kg; intra- and postoperative CRI 20 µg/kg/min], (2) fentanyl (Fentanest; Cristália Prod. Quim. Farm. Ltda, Brazil) [group fentanyl (GF) (n=5): bolus 5 µg/kg; intraoperative CRI 5 µg/kg/hour and postoperative CRI 2 µg/kg/hour], or (3) ketamine-fentanyl [group ketamine and fentanyl (GKF) (n=6): aforementioned doses].

The CRI loading dose was administered 5 min before skin incision. Intraoperative CRI started immediately after bolus administration and ended after animal’s extubation. A new solution containing the doses previously mentioned for each group was prepared for postoperative
defined as the synchronization of the animal’s R with the SAP in the preoperative and postoperative periods; invasion and Company, USA) (Roche Cobas B121; Roche Diagnostica Brasil Ltda., Brasil). The drugs were monitored in positive ionization mode (ESI⁺); ion ratios (m/z) of ketamine [M + H⁺] and fentanyl [M + H⁺] are 238.189/125.00 and 337.350/105.100, respectively. Plasma samples were thawed and 125 µL aliquots were pipetted to Eppendorf tubes; 25 µL of propranolol (500.00 ng/mL; internal standard) and 25 µL of 0.1 M sodium hydroxide were added to the sample of 1 mL of the extraction mixture (MTBE: 80:20 dichloromethane). The samples were centrifuged for 5 min at 8000 g, and 700 µL of the supernatant was transferred to a test tube. After drying at 40 °C with dry air at a constant flow of 25 kgf/m², the samples were reconstituted with 250 µL of the mobile phase and 10 µL was injected into the HPLC–MS/MS system. The samples were analyzed against calibration curves prepared using white canine plasma contaminated with known concentrations of ketamine (0.10 – 5000.00 ng/mL) and fentanyl (0.10 – 150.00 ng/mL) with R² of 0.99 and calculated weight of 1/X².

Postoperative pain scores were evaluated according to the short version of Glasgow Composite Measure Pain Score (GCPS) [18] and mechanical nociceptive threshold (MNT), after the end of the surgical procedure and extubation every 15 min in the first hour, after that every 120 min for up to 12 h, and 7 and 14 days. The short form of GCPS includes 6 behavioral categories with associated descriptive expressions of vocalization, attention to wound, mobility, response to touch, demeanor, and posture/activity. The assessment of MNT was carried out with a Von Frey digital algometer (digital analgesimeter; INSIGHT®, Brazil). The evaluation area was the 1 – 3 cm region around the surgical wound, which was evaluated at 6 different points (two points in regions thoracic, abdominal, and inguinal on the right and left sides) and averaged.

Postanaesthetic sedation was assessed according to the scores developed by Bergadano and colleagues, (2009) [19], throughout the postoperative period. Behavioral changes throughout the infusion period were also recorded, such as increasing locomotor activity, head and neck stereotypical movements, twitching, sialorrhea, tearing and emesis.
Rescue analgesia
If the postoperative pain scores were >5 points (5/20), morphine (0.1 mg/kg IV) was administered, and the animal was reassessed after 10 min of administration; if necessary, a new dose was administered. The number of analgesic rescues was documented throughout the assessment.

In the interval between the 12 and 24 h evaluations, the analgesic evaluation using GCPS was performed every 4 h to guarantee adequate analgesia to the animal in the interval among the evaluations. If there was a need to anticipate the analgesic rescue, the data obtained were considered for the time point 24 h, and the exact time of administration of the rescue was presented descriptively.

Statistical analysis
Power test was performed using statistics software (SigmaPlot for Windows) for a sample size calculation. The normality of data distribution was checked using Shapiro–Wilk Test. Statistical analyses were performed using GraphPad Prism 8 (GraphPad Software Inc., CA, USA) for Windows. The data related to HR, fR, arterial pressure, FE CO₂, SpO₂, plasma concentration, and MNT are presented as means ± standard deviations and subjected to analysis of variance for repeated measures, followed by Tukey’s test, for comparison among the time points within each group and among groups at each time point.

To evaluate sedation, and analgesia using the Glasgow Scale the Kruskal–Wallis test was used, followed by the Dunn’s test for comparison among time points within the same group and among groups at each time point. A significance level of 5% (P ≤ 0.05) was set as the threshold.

Results
A total of 58 dogs were screened for enrolment in the study, but only 18 met the inclusion criteria. A female dog from the GF was withdrawn from the study after data collection because she presented complications during the surgical procedure that required another surgical intervention.

The mean expired isoflurane fractions during anesthesia were 1.52 V%, 0.98 V%, and 1.2 V% in the GK, GKF, and GF, respectively.

There was no difference in the number of analgesic rescues among the groups studied. It was observed that analgesic rescues occurred later in the GF than in the GK and GKF. Requirements for analgesic rescues were verified up to 6 h in the GK and GKF and only from 6 h in the GF. In the GK, one animal (1/6) received rescue at 15 min and another at 2 h; in the GKF, two animals (2/6) received rescue at 2 h; in the GF, one (1/5) animal received rescue at 6 h and another at 8 h.

Cardiorespiratory variables
The results corresponding to cardiorespiratory parameters in the intraoperative and postoperative period are shown in Tables 1 and 2.

The arterial blood gas results are shown in Table 3.

Pharmacokinetic parameters
There was no difference in the plasma concentration of ketamine and fentanyl, maximum concentration, and clearance among the groups studied (Table 4).

The maximum observed ketamine concentration 5 min after the bolus administration in the GK and GKF were 2847.06 ± 2903.03 and 2811.20 ± 1931.76 ng/mL, respectively (Fig. 1). The postoperative ketamine infusion was sufficient to maintain plasma concentrations of >100 ng/mL in all animals treated with fentanyl (5/5) and only in two animals treated exclusively with ketamine (2/5).

An infusion of 5 µg/kg/hour of fentanyl during the operation was sufficient to maintain plasma levels of >1.1 ng/mL in 4/5 animals in the GKF (2.51 ± 1.18) and 3/4 animals in the GF (2.96 ± 1.79). The increase of ketamine in the GKF did not significantly change the plasma concentration of fentanyl during the intraoperative period, compared to the GF.

Sedation and analgesia
The results related to MNT are shown in Fig. 2. Regardless of the group evaluated, a significant reduction in MNT up to 12 h after the operation (P < 0.03) was observed; at T24h it remained significantly lower than at baseline in groups GK (P = 0.03) and GKF (P = 0.02). MNT values returned to baseline level in all groups on postoperative day 7. Higher sedation scores were found at time points between 15 and 30 min than at baseline in the GKF (P < 0.02), GK (P < 0.009), and GF (P < 0.04).

There were no significant differences in pain scores recorded with GCPS among groups (Fig. 3).

The following psychomimetic changes were observed: GF: vocalization in 1/5 animals; GK: salorrhea in 3/6 animals and vocalization in 1/6 animals; and GKF: vocalization in 1/6 animals.

Discussion
The main findings of this study were as follows: a) The infusions did not trigger significant cardiovascular changes in any of the groups throughout the experimental phases; b) all groups experienced satisfactory analgesia during the intraoperative period; c) there was no significant differences between groups regarding postoperative analgesia during the 24-h period; d) fentanyl and ketamine doses used did not promote a
steady state, but guaranteed minimal plasma levels with potential for analgesia during the 8 h of administration.

The reduction in HR observed in the groups treated with fentanyl was already expected, considering that the action on μ opioid receptors inhibits voltage-dependent calcium channels, reducing neurotransmission by cardiac vagal neurons [20]. Although a reduction in HR was observed, this did not trigger significant hemodynamic repercussions even during the perianesthetic period.

The ketamine-fentanyl association did not culminate in the sympathetic stimulation expected by the use of ketamine [10, 13]. However, when infused alone, the drug contributed to the maintenance of HR at a level close to the baseline levels during the infusion period. This effect is due to the activation of adrenergic receptors and the alteration of the calcium flow to the intracellular medium with positive inotropism, along with a reduction in the bradycardia-inducing effect of fentanyl. The sympathetic effects of ketamine such as increasing HR have been

---

Table 1

| Variable       | Group | Baseline | 5 | 15 | 25 | 35 | 45 | 55 | 65 | 75 |
|----------------|-------|----------|---|----|----|----|----|----|----|----|
| Heart rate (beats minute⁻¹) | GK    | 104 ± 13 | 129 ± 27 | 126 ± 32 | 120 ± 42 | 123 ± 33 | 117 ± 22 | 120 ± 16 | 113 ± 16 | 115 ± 13 |
|                | GKF   | 110 ± 22 | 87 ± 9  | 71 ± 8⁸ | 69 ± 6⁹ | 72 ± 16⁹ | 66 ± 14⁹ | 72 ± 24⁹ | 75 ± 16⁹ | 82 ± 16⁹ |
|                | GF    | 97 ± 35  | 113 ± 32 | 88 ± 25⁰ | 57 ± 15⁰ | 58 ± 10⁰ | 71 ± 13⁰ | 68 ± 15⁰ | 66 ± 11⁰ | 69 ± 12⁰ |
| f₀ (breaths minute⁻¹) | GKF   | 30 ± 10  | 17 ± 1⁴ | 16 ± 1⁴ | 15 ± 1⁴ | 15 ± 1⁴ | 16 ± 2⁴ | 16 ± 2⁴ | 16 ± 2⁴ |
|                | GF    | 34 ± 14  | 17 ± 2⁴ | 16 ± 1⁴ | 15 ± 2⁴ | 15 ± 1⁴ | 14 ± 3⁴ | 15 ± 1⁴ | 14 ± 3⁴ |
|                | -     | 75 ± 14  | 70 ± 16 | 74 ± 13 | 90 ± 8⁴ | 81 ± 13 | 78 ± 10 | 77 ± 11 | 77 ± 9  |
| MAP (mmHg)     | GK    | 74 ± 7   | 72 ± 9  | 60 ± 14 | 66 ± 10⁸ | 72 ± 12 | 76 ± 15 | 77 ± 6  | 79 ± 9  |
|                | GKF   | 73 ± 6   | 75 ± 8  | 73 ± 2  | 81 ± 15⁸ | 89 ± 20 | 65 ± 40 | 87 ± 25 | 74 ± 10 |
|                | GF    | 99 ± 2   | 99 ± 2  | 99 ± 2  | 99 ± 1  | 99 ± 1  | 99 ± 1  | 99 ± 1  | 99 ± 2  |
|                | -     | 98 ± 1   | 98 ± 1  | 97 ± 2  | 97 ± 2  | 97 ± 1  | 97 ± 1  | 98 ± 1  | 98 ± 1  |
| SpO₂ (%)       | GK    | 36 ± 6   | 35 ± 6  | 34 ± 3  | 35 ± 4  | 34 ± 2  | 33 ± 5  | 34 ± 5  | 34 ± 5  |
|                | GKF   | 27 ± 6   | 31 ± 1  | 31 ± 1  | 30 ± 3  | 32 ± 4  | 31 ± 2  | 32 ± 4  | 32 ± 5  |
|                | GF    | 28 ± 2   | 30 ± 3  | 31 ± 4  | 33 ± 5  | 32 ± 4  | 33 ± 5  | 32 ± 5  | 31 ± 5  |

a, b Significant difference between group. * Significant difference in treatment with a basal time point. HR Heart rate, f₀ respiratory rate, MAP mean arterial pressure, SpO₂ pulse oximetry, FE CO₂ end-tidal carbon dioxide.

Table 2

| Variable       | Group | Baseline | 0.25 | 0.5 | 1 | 2 | 4 | 6 | 8 | 12 |
|----------------|-------|----------|------|----|---|---|---|---|---|----|
| Heart rate (beats minute⁻¹) | GK    | 104 ± 13 | 107 ± 14⁸ | 96 ± 20 | 87 ± 10⁴ | 95 ± 14³ | 86 ± 13 | 86 ± 13 | 98 ± 39 | 101 ± 14 |
|                | GKF   | 110 ± 22 | 104 ± 13³ | 97 ± 9  | 89 ± 7³ | 87 ± 14³ | 90 ± 13 | 90 ± 7  | 95 ± 14 | 94 ± 16 |
|                | GF    | 97 ± 35  | 82 ± 24⁰ | 71 ± 13 | 70 ± 20⁴ | 75 ± 21⁴ | 65 ± 17⁴ | 79 ± 14 | 83 ± 18 | 83 ± 17 |
| f₀ (breaths minute⁻¹) | GK    | 30 ± 10  | 40 ± 23 | 36 ± 15 | 43 ± 12³ | 47 ± 11³ | 37 ± 18 | 32 ± 10 | 30 ± 10 | 43 ± 47 |
|                | GKF   | 34 ± 14  | 44 ± 41 | 39 ± 23 | 45 ± 23 | 52 ± 39 | 35 ± 13 | 36 ± 11 | 29 ± 10 | 35 ± 15 |
|                | GF    | 28 ± 4   | 54 ± 21 | 44 ± 25 | 68 ± 37 | 43 ± 27 | 29 ± 17 | 33 ± 20 | 38 ± 19 | 27 ± 7  |
| SAP mmHg       | GK    | 136 ± 25 | 137 ± 9³ | 139 ± 12 | 136 ± 15 | 148 ± 17 | 144 ± 17 | 140 ± 22 | 143 ± 16 |
|                | GKF   | 153 ± 13 | 153 ± 1³ | 155 ± 18 | 151 ± 17 | 170 ± 28 | 160 ± 15 | 160 ± 21 | 151 ± 12 | 143 ± 21 |
|                | GF    | 136 ± 13 | 132 ± 2³ | 163 ± 12 | 148 ± 8  | 138 ± 35 | 136 ± 15 | 141 ± 10 | 158 ± 7³ | 147 ± 3 |

a, b, c Significant difference between group. * Significant difference in treatment with a basal time point. HR Heart rate, f₀ respiratory rate, SAP systolic arterial pressure.
de Moura et al. BMC Veterinary Research (2022) 18:225
Page 6 of 10

Table 3 Mean ± standard deviation values of arterial blood gas analyses in dogs treated with ketamine (GK: bolus 0.5 mg kg⁻¹; CRI 20 µg kg⁻¹ min⁻¹ in intra- and postoperative periods), fentanyl (GF: bolus 5 µg kg⁻¹; intraoperative CRI 5 µg kg⁻¹ h⁻¹ and postoperative CRI 2 µg kg⁻¹ h⁻¹), or combination of ketamine-fentanyl (GKF: aforementioned doses) in intraoperative and postoperative period

| Variable                      | Group | Anesthesia (minutes) | Postoperative (hours) |
|-------------------------------|-------|----------------------|-----------------------|
|                               |       | 20                   | 40  | 60  | 80  | 1   | 4   | 8   |
| pH                            | GK    | 7.30±0.08            | 7.29±0.07             | 7.29±0.06             | 7.31±0.06             | 7.33±0.04            | 7.39±0.02            | 7.38±0.04            |
|                               | GKF   | 7.36±0.06            | 7.33±0.06             | 7.31±0.05             | 7.27±0.04#            | 7.34±0.02            | 7.38±0.03            | 7.41±0.01            |
|                               | GF    | 7.29±0.08            | 7.27±0.04#            | 7.27±0.03#            | 7.25±0.02#            | 7.33±0.01            | 7.37±0.02            | 7.41±0.01            |
| PaO₂ (mmHg)                   | GK    | 304.6±89.2           | 319.8±80.2            | 304.4±88.0            | 293.5±44              | 80.4±3.0             | 90.8±13.9            | 83.7±7.9             |
|                               | GKF   | 300.9±62.3           | 328.1±106.2           | 296.2±89.8            | 290.3±89.8            | 78.2±6.6             | 794±5.6              | 80.7±6.3             |
|                               | GF    | 291.5±4.07           | 274.2±36.1            | 266.5±29.0            | 282.7±88.9            | 80.8±3.1             | 84.3±5.0             | 84.2±5.4             |
| PaCO₂ (mmHg)                  | GK    | 45.9±11.2            | 46.4±10.2             | 45.2±8.5              | 42.9±6.3              | 40.9±4.2             | 31.4±1.7             | 32.3±1.5             |
|                               | GKF   | 38.7±6.1             | 40.6±6.9              | 43.0±5.8              | 48.5±8.5#             | 43.3±4.3             | 36.3±2.0             | 33.1±2.1             |
|                               | GF    | 44.2±15.3            | 44.6±8.8              | 43.3±6.9              | 46.8±5.3              | 41.5±2.2             | 34.3±3.9             | 35.3±1.1             |
| HCO₃⁻ (mmol L⁻¹)              | GK    | 21.8±1.8             | 21.3±1.3              | 20.8±1.5              | 20.9±0.8              | 21.1±2.0             | 18.6±0.4             | 18.6±0.7             |
|                               | GKF   | 21.0±0.5             | 20.9±0.7              | 20.8±0.8              | 21.8±1.7              | 23.2±1.2             | 21.1±1.2             | 20.3±1.2             |
|                               | GF    | 7.30±0.08            | 20.8±3.0              | 20.1±2.5              | 20.6±2.4              | 21.0±0.7             | 19.7±2.6             | 21.2±0.3             |

*# Significant difference in treatment with a basal time point. pH; arterial partial pressure of oxygen (PaO₂); arterial partial pressure of carbon dioxide (PaCO₂); arterial bicarbonate (HCO₃⁻)*

Table 4 Mean ± standard deviation of the pharmacokinetic parameters of ketamine and fentanyl in plasma samples of dogs treated with ketamine (GK: bolus 0.5 mg kg⁻¹; CRI 20 µg kg⁻¹ min⁻¹ in intra- and postoperative periods), fentanyl (GF: bolus 5 µg kg⁻¹; intraoperative CRI 5 µg kg⁻¹ h⁻¹ and postoperative CRI 2 µg kg⁻¹ h⁻¹), or combination of ketamine-fentanyl (GKF: aforementioned doses)

| Group | AUC     | Cmax (ng mL⁻¹) | Cl (mL minute⁻¹ kg⁻¹) |
|-------|---------|----------------|-----------------------|
| KET   | GK      | 385.45±1698.62| 2894.62±2860.39       | 0.034±0.034           |
|       | GKF     | 8686.15±7290.39| 2217.34±1927.83       | 0.024±0.018           |
|       | GF      | 7.84±2.53     | 3.9±0.81              | 0.041±0.026           |
| FENT  | GKF     | 7.45±4.12     | 5.3±1.77              | 0.063±0.048           |

*Area under the curve (AUC); clearance (Cl); maximum plasma concentration (Cmax)*

demonstrated by infusions delivering doses of ≥ 40 µg/kg/hour in awake dogs [10].

Despite the reduction in HR observed over the intraoperative period in the GF, the reduction in MAP was only observed at 35 min of anesthesia compared to the GK. MAP was maintained at > 60 mmHg without the use of vasoactive drugs in any of the animals, possibly due to a lower requirement for isoflurane, attributed to the analgesic effect of both premedication and infusions [11, 21].

The absence of significant changes in blood gas values during surgery demonstrated the effectiveness of the ventilation mode and the adjustment adopted for the study. Although respiratory depression attributed to fentanyl has already been described for infusions with a dose of 4 µg/kg/hour [5], which is close to the dose used in our study (2–5 µg/kg/hour), others authors did not observe any ventilatory changes that could be recognized in the blood gas analysis [4, 7]. It was not possible to state that the treatment with fentanyl did not promote respiratory depression depending on the ventilatory support used; however, the presence of apnea in dogs treated with fentanyl, as verified by the synchronization with the ventilator, demonstrates the need for ventilatory support in the intraoperative period.

A preliminary study published by our group demonstrated that a dose of 20 µg/kg/min was safe [10]; the dose of ketamine used in the infusion in this study was based on these findings. Doses of 10 µg/kg/min have been reported in previous studies with controversial results related to analgesia [19, 22], and in a study conducted by Sarrau and colleagues [22], this dose was considered to be unable to promote adequate analgesia. These described results supported the use of a dose of 20 µg/kg/min.
The doses of ketamine used in this study were not able to promote a steady state during the infusion; it was possible to observe large variations in concentrations among individuals throughout the evaluated time points. The highest plasma concentration was observed in the first minute of infusion because of the bolus administration. Even at high doses of infusion, such as 30 and 50 µg/kg/min [13], the steady state was not observed after the bolus administration. This lack of steady state can be explained by the fast clearance of the drug; therefore, high infusion doses for a prolonged period are required for at least five half-lives [13].

The large variations in the maximum plasma concentrations observed among individuals and among studies are justified by the differences in doses [19], intraspecific differences [23], high drug clearance rate [13], and the variations related to biotransformation by cytochrome P450 [24]. Ketamine is biotransformed by the cytochrome P450 enzyme family, mainly by the CYP2B6, CYP2C9, and CYP3A4 isoforms [24, 25].

To our knowledge, no previous study conducted pharmacokinetic evaluation of ketamine associated with fentanyl and evaluated the influence of one drug on the
plasma concentrations and the clearance rate of the other. The individual plasma concentrations of ketamine in the GKF were higher than those in the GK throughout the infusion period. The GKF was able to maintain a plasma levels above 160 ng/mL for up to 8 h in all animals (5/5), whereas the GK showed plasma levels of > 110 ng/mL in only one animal (1/5).

The CYP3A4 isoform is responsible for the biotransformation of fentanyl [26]. It is believed that the adoption of fentanyl in the protocol resulted in an increase in plasmatic concentrations, probably through alteration of ketamine metabolism and biotransformation. Fentanyl, by reducing HR, can also alter cardiac output, thereby altering the clearance and redistribution of ketamine [27, 28].

Plasma fentanyl concentrations showed a peak 5 min after the bolus administration, which decreased gradually over the infusion period. Similar ketamine infusions, fentanyl infusions showed no steady state throughout the infusion. The minimum effective analgesic range for fentanyl was reported to be 0.95 – 2.00 ng/mL for dogs and humans [29–32]. The plasma fentanyl concentrations observed in our study were maintained within analgesic levels for up to one hour, with the decrease coinciding with the reduction in the infusion rate in the postoperative period. The infusion rate was reduced after the end of anesthesia to decrease the cumulative effect and consequent respiratory depression, commonly observed with the use of µ agonist opioids [5, 6], and because of the absence of studies showing the cardiovascular and respiratory impact of prolonged fentanyl infusion.

Regardless of the treatment, the drugs were not sufficient to maintain the nociceptive threshold close to baseline levels in the first 12 h. However, GCPS indicated that the animals were not showing signs of significant pain. Postoperative pain induced by mastectomy is mainly caused by the inflammatory response to surgical trauma, by peripheral sensitization; when not treated correctly, it can lead to the activation of long-term stimulation mechanisms, with consequent hyperalgesia [33].

Although the scale used has not been validated for evaluating mastectomy-related pain, the results, obtained by an experienced evaluator, indicated that the animals remained comfortable in the postoperative period; however, superiority of the treatments could not be evaluated. The reduction of MNT demonstrated that the drugs used in the treatments were not able to prevent peripheral sensitization, which is normally prevented with the use of drugs of other classes that prevent the conduction of primary afferent sensory fibers or have an anti-inflammatory action.

Ketamine is known to reduce acute pain in the postoperative period [3], but evidence suggesting its long-term benefits and a decreased in the requirement of opioid analgesics is still limited [3, 8]. Although the superiority of analgesia with increased ketamine to fentanyl compared to its isolated use was not evident, the results corresponding to the GK were sufficient to demonstrate that ketamine infusion shows analgesic effect without the association with opioid as indicated by the plasma concentrations. In dogs, use of ketamine in multimodal infusion protocols [13] or as a bolus [9, 34] demonstrated a decrease in MNT at the surgical site in dogs after surgical procedure [9, 34], as well as in GCPS scores [9], thus demonstrating a decrease in central sensitization with an improvement in intra- and postoperative analgesia, but without decreasing peripheral sensitization.

Fentanyl bolus administration allows a decrease in MNT for a short time [35], whereas a CRI regimen was shown to increase the thermal thresholds for up to 300 min during the infusion [36]. However more studies are warranted to conclude the effect of continuous infusion on nociceptive mechanical threshold.

The treatments contributed to reduce postoperative pain and contributing to the recovery of the animals, as indicated by the MNT values with return to baseline values in all animals on the 14th day of assessment.

The limitations of this study were the characteristics of a clinical study, in which variables related to an individual are large. To minimize these impacts, the selection of animals was judicious, which led to a reduction in the number of animals/group and may have reduced the magnitude of differences among treatments, especially regarding pharmacokinetic behavior. Another issue that may have influenced the demonstration of differences among treatments regarding MNT, is related to the use of NSAIDs after the end of the infusion. The authors believe that despite the limitations, the results presented are significant.

**Conclusion**

The infusion of ketamine, alone or in combination with fentanyl, could promote satisfactory analgesia in the intra and postoperative periods, and the doses used did not cause cardiorespiratory changes requiring cessation of its use in the postoperative period for up to 8 h. All infusions led to the maintenance of analgesic plasma concentrations, but the addition of fentanyl to ketamine treatment promoted an increase in plasma ketamine concentration. The treatments tested are suitable protocols to be considered for balanced anaesthesia during unilateral total mastectomy. Further studies are required to determine the impact of one drug on the other’s biotransformation.

**Abbreviations**

CRI: Constant rate infusion, GK: Treatment group ketamine, GF: Treatment group fentanyl, GKF: Treatment group ketamine-fentanyl, ASA: American...
Acknowledgements

The authors would like to thank the CNPq for funding this research; the Veterinary Hospital of Escola de Veterinária e Zootecnia of Universidade Federal de Goiás for facilitating the implementation of the screening of volunteer patients for the project and performing surgical procedures; and Cristália Farmaceutic Industry for their assistance in executing the pharmacokinetic analyses.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Funding

Research funded by Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq (nº 457140/2014–3).

Declarations

Ethics approval and consent to participate

The study was carried out in compliance with the ARRIVE guidelines. The study was conducted after written owner consent was obtained and approval by the Universidade Federal de Goiás (UFG) Ethics Committee on The Use of Animals (CEUA – UFG nº 010/2014). UFG – CEUA is licensed according to Brazilian law number 11.794, dated 10/08/2008, and Normative Resolution number 01, dated 09/07/2010, of the National Council of Animal Experimentation (CONCEA).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Veterinary Medicine, Federal University of Goiás, 74690-900, Goiânia, GO, Brazil. 2 Development and Technological Innovation in Drugs - Farmatec, Research Center, Universidade Federal de Goiás, Goiânia, GO, Brazil.

Received: 8 July 2021 Accepted: 28 February 2022 Published online: 14 June 2022

References

1. Crociolli GC, Cassu RN, Barbero RC, Rocha TL, Gomes DR, Nicacio GM. Gabapentin as an adjuvant for postoperative pain management in dogs undergoing mastectomy. J Vet Med Sci. 2015;77(8):1011–S. https://doi.org/10.1292/jvms.15-0602.

2. Horta RS, Figueiredo MS, Lavalle GE, Costa MP, Cunha RM, Araújo RB. Surgical stress and postoperative complications related to regional and radical mastectomy in dogs. Acta Vet Scand. 2015;57(1):1. https://doi.org/10.1186/s13038-015-0121-3.

3. Humbler SR, Dalton AJ, Li L. A systematic review of therapeutic interventions to reduce acute and chronic post-surgical pain after amputation, thoracotomy or mastectomy. Eur J Pain. 2015;19(4):451–65. https://doi.org/10.1002/ep.2567.

4. Amengual M, Leigh H, Rijo E. Postoperative respiratory effects of intra-venous fentanyl compared to intravenous methadone in dogs following spinal surgery. Vet Anaesth Analg. 2017;44(5):1042–8. https://doi.org/10.1016/j.vaa.2016.11.010.

5. Bufalari A, Di Meco A, Nannarone S, Padua S, Adami C. Fentanyl or sufentanil continuous infusion during isoflurane anaesthesia in dogs: clinical experiences. Vet Res Commun. 2007;31:277. https://doi.org/10.1007/s11259-007-0046-z.

6. Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747–58. https://doi.org/10.1093/bja/aen094.

7. Romano M, Portela DA, Breghi G, Otero PE. Stress-related biomarkers in dogs administered regional anaesthesia or fentanyl for analgesia during stifle surgery. Vet Anaesth Analg. 2016;43(1):44–54. https://doi.org/10.1111/vaa.12275.

8. Gutierrez-Blanco E, Victoria-Mora JM, Ibancovich-Camarillo JA, Saurí-Arceo CH, Bollo-González ME, Acevedo-Arcique CM, Marín-Cano G, Stea-gall PV. Postoperative analgesic effects of either a constant rate infusion of fentanyl, lidocaine, ketamine, dexmedetomidine, or the combination lidocaine-ketamine-dexmedetomidine after ovariohysterectomy in dogs. Vet Anaesth Analg. 2015;42(3):309–18. https://doi.org/10.1111/vaa.12215.

9. Kafka Li, Rahman NA, Abubakar AA, Cohn YM, Fukaruzi S, Omar MA, Chen HC. Pre-emptive multimodal analgesia with tramadol and ketamine–lidocaine infusion for suppression of central sensitization in a dog model of ovariohysterectomy. J Pain Res. 2018;11:743. https://doi.org/10.2147/JPR.152475.

10. Franco LG, Wilges CH, Junior DP, Cerejo SA, Nishimura LT, Bittar IP. Effects of ketamine constant rate infusions on cardiac biomarkers and cardiac function in dogs. Vet Anaesth Analg. 2018;45(3):250–9. https://doi.org/10.1116/vaa.2017.10.007.

11. Aguado D, Benito J, de Segura I. Reduction of the minimum alveolar concentration of isoflurane in dogs using a constant rate of infusion of lidocaine–ketamine in combination with either morphine or fentanyl. Vet J. 2011;189(1):63–6. https://doi.org/10.1016/j.tvjl.2010.05.029.

12. Wang HJ, Chang SC, Lee WM, Chen KS, Wang HC. Comparison of Onsite Infiltration and Constant Rate Infusion for Postoperative analgesia in dogs with Mammary Tumors Undergoing bilateral radical mastectomy and ovariohysterectomy. Taiwan Vet J. 2017;43(03):177–83. https://doi.org/10.1142/S15247500044.

13. Kafka Li, Saifullah B, Abubakar AA, Cohn YM, Fukaruzi S, Kafka A, Behan EA, Ebrahim M, Chen HC. Serum concentration of ketamine and antinociceptive effects of ketamine and ketamine-lidocaine infusions in conscious dogs. BMC Vet Res. 2016;12(1):198. https://doi.org/10.1186/s12917-016-0815-4.

14. Misdorp W. Histological classification of the mammary tumors of the dog and the cat. World Health Organ Int Histological Classif Tumors Domest Anim Second Ser. 1999;7:1–59.

15. Fossum TW, Possen TW, Duprey LP, O’Connor D. Small animal surgery. St Louis: Mosby Elsevier. 2007.

16. Toki H, Ichikawa T, Mizuno-Yashii A, Yamaguchi J. A rapid and sensitive chiral LC–MS/MS method for the determination of ketamine and nor- ketamine in mouse plasma, brain and cerebrospinal fluid applicable to the stereoselective pharmacokinetic study of ketamine. J Pharm Biomed Anal. 2018;148:268–97. https://doi.org/10.1016/j.jpba.2017.09.033.

17. Huynh NH, Tyfors N, Ekman L, Johansson M. Determination of fentanyl in human plasma and fentanyl norfentanyl in human urine using LC–MS/MS. J Pharm Biomed Anal. 2005;37(5):1095–100. https://doi.org/10.1016/j.jpba.2004.09.024.

18. Reid J, Nolan AM, Hughes JM, Lascalles D, Prawson P, Scott EM. Development of the short-form Glasgow Composite Measure Pain Scale (CMPS-P) and derivation of an analgesic intervention score. Anim Welf Potters Bar Then Wheatheamstead. 2007;16:97.

19. Bergadano A, Andersen OK, Arendt-Nielsen L, Theurrill R, Thornm W, Spadavecchia C. Plasma levels of a low-dose constant-rate-infusion of ketamine and its effect on single and repeated nociceptive stimuli in conscious dogs. Vet J. 2009;189(1):63–6. https://doi.org/10.1016/j.tvjl.2009.05.002.

20. Griffiths KJ, Venkatesan P, Huang ZG, Wang X, Bouairi E, Evans C, Gold A, Mendelowitz D. Fentanyl inhibits GABAergic neurotransmission to cardiac
vagal neurons in the nucleus ambiguus. Brain Res. 2004;1007(1–2):109–15. https://doi.org/10.1016/j.brainres.2004.02.010.

21. Williamson AJ, Soares JH, Pavlisko ND, Council-Troche RM, Henao-Guerrero N. Isoflurane minimum alveolar concentration sparing effects of fentanyl in the dog. Vet Anaesth Analg. 2017;44(4):736–45. https://doi.org/10.1016/j.vaa.2017.02.002.

22. Sarras S, Jourdan J, Dupuis-Soyer F, Verwaerde P. Effects of postoperative ketamine infusion on pain control and feeding behaviour in bitches undergoing mastectomy. J Small Anim Pract. 2007;48(1):670–6. https://doi.org/10.1111/j.1748-5827.2007.00362.x.

23. Pyependop BH, Ikkiw JE. Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. Am J Vet Res. 2005;66(12):2034–8. https://doi.org/10.2460/ajvr.2005.66.2034.

24. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41. https://doi.org/10.1016/j.pharmthera.2012.12.007.

25. Saba R, Kaye AD, Urman RD. Pharmacogenomics in pain management. Anesthesiol Clin. 2017;35(2):295–304. https://doi.org/10.1016/j.anclin.2017.01.015.

26. Wilde M, Pichini S, Pacifici R, Tagliabracci A, Busardo FP, Auwärter V, Solimini R. Metabolic pathways and potencies of new fentanyl analogs. Front Pharmacol. 2019;10:238. https://doi.org/10.3389/fphar.2019.00238.

27. Machado ML, Soares JH, Pyependop BH, Henao-Guerrero N, Pavlisko ND, Ross J. Effect of heart rate on the pharmacokinetics of fentanyl in dogs anesthetized with isoflurane and hydromorphone. Vet Anaesth Analg. 2019;46(6):736–44. https://doi.org/10.1016/j.vaa.2019.06.005.

28. Williamson AJ, Soares JH, Henao-Guerrero N, Council-Troche RM, Pavlisko ND. Cardiovascular and respiratory effects of two doses of fentanyl in the presence or absence of bradycardia in isoflurane-anesthetized dogs. Vet Anaesth Analg. 2018;45(4):423–31. https://doi.org/10.1016/j.vaa.2018.03.001.

29. Keating SC, Kerr CL, Valverde A, Johnson RJ, McDonell WN. Cardiopulmonary effects of intravenous fentanyl infusion in dogs during isoflurane anesthesia and with concurrent acepromazine or dexmedetomidine administration during anesthetic recovery. Am J Vet Res. 2013;74(5):672–82. https://doi.org/10.2460/ajvr.74.5.672.

30. Robinson TM, Kruse-Elliott KT, Markel MD, Pluhar GE, Massa K, Bjorling DE. A comparison of transdermal fentanyl versus epidural morphine for analgesia in dogs undergoing major orthopedic surgery. J Am Anim Hosp Assoc. 1999;35(2):95–100. https://doi.org/10.5326/15473317-35-2-95.

31. Sano T, Nishimura R, Kanazawa H, Igarashi E, Nagata Y, Mochizuki M, Sasuki N. Pharmacokinetics of fentanyl after single intravenous injection and constant rate infusion in dogs. Vet Anaesth Analg. 2006;33(4):266–73. https://doi.org/10.1111/j.1748-5827.2007.00362.x.

32. Pak DJ, Yong RJ, Kaye AD, Urman RD. Chronification of pain: mechanisms, current understanding, and clinical implications. Curr Pain Headache Rep. 2018;22(2):1–6. https://doi.org/10.1007/s11916-018-0666-8.

33. Sasaki N. Pharmacokinetics of fentanyl after single intravenous injection in awake cats. Vet Anaesth Analg. 2017;44(4):736–45. https://doi.org/10.1016/j.vaa.2017.02.002.

34. Carozzo MV, Alcorn J, Ambros B. Effects of two fentanyl constant rate infusions on thermal thresholds and plasma fentanyl concentrations in awake cats. Vet Anaesth Analg. 2018;45(6):831–8. https://doi.org/10.1016/j.vaa.2018.06.006.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.